Vis enkel innførsel

dc.contributor.authorKvinge, Alexander Dåtland
dc.contributor.authorKvammen, Tobias
dc.contributor.authorMiletic, Hrvoje
dc.contributor.authorBindoff, Laurence Albert
dc.contributor.authorReikvam, Håkon
dc.date.accessioned2022-12-19T13:42:38Z
dc.date.available2022-12-19T13:42:38Z
dc.date.created2022-12-05T09:17:49Z
dc.date.issued2022
dc.identifier.issn1198-0052
dc.identifier.urihttps://hdl.handle.net/11250/3038596
dc.description.abstractMusculoskeletal graft versus host disease (GVHD) is a rare manifestation of chronic GVHD (cGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Left untreated, the disease can cause extensive damage to muscle tissue and joints. We describe a 62-year-old male with musculoskeletal GVHD and generalized muscle pain and stiffness. In addition, we performed a systemic literature review based on published cases of musculoskeletal GVHD between 1983 and 2019. We identified 85 cases, 62% male and 38% female with an age of 4–69 years and median age of 39 years at diagnosis. The majority of patients (72%) also had manifestations of cGVHD in at least one other organ system, most frequently the skin (52%), followed by oropharyngeal mucosa (37%), and pulmonary and gastrointestinal tract (GI tract) (21%). We conclude that, while musculoskeletal cGVHD is a rare complication of allo-HSCT, it remains a serious and debilitating risk that must be considered in patients with muscle pain, muscle weakness, joint stiffness, and tissue inflammation. Early intervention is critical for the patient’s prognosis.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleMusculoskeletal Chronic Graft versus Host Disease-A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literatureen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3390/curroncol29110663
dc.identifier.cristin2088441
dc.source.journalCurrent Oncologyen_US
dc.source.pagenumber8415-8430en_US
dc.identifier.citationCurrent Oncology. 2022, 29 (11), 8415-8430.en_US
dc.source.volume29en_US
dc.source.issue11en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal